#United States #Class Action #Philadelphia #Pomerantz Law Firm #INOVIO Pharmaceuticals

Pomerantz Law Firm Initiates Class Action Against Inovio Pharmaceuticals

On April 2, 2026, Pomerantz LLP revealed the filing of a class action lawsuit against Inovio Pharmaceuticals, Inc., listed on NASDAQ as INO, along with certain of its officers. This legal action occurs in the United States District Court for the Eastern District of Pennsylvania. It seeks restitution on behalf of all individuals or entities, excluding the defendants, who acquired Inovio securities from October 10, 2023, to December 26, 2025, both inclusive. The case, registered under docket number 26-cv-00803, focuses on alleged breaches of the federal securities laws as stated under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5.

Investors who purchased or otherwise obtained Inovio securities within the class period are encouraged to take action by April 7, 2026, to request the Court appoint them as Lead Plaintiff for the class. More details regarding the lawsuit and how to join can be accessed through Pomerantz’s dedicated website.

The Nature of Inovio's Business

Inovio Pharmaceuticals is a biotechnology company engaged in the discovery and commercialization of DNA medicines aimed at treating diseases associated with human papillomavirus (HPV), among other diseases. Their strategic focus involves utilizing DNA plasmids that act as a blueprint for the body’s cells to produce proteins targeting specific diseases. A key device in this strategy is their proprietary medical device, CELLECTRA, which purportedly enhances the delivery of their DNA medicines into cells, optimally facilitating therapeutic effects.

Among their portfolio, Inovio’s primary product candidate is INO-3107, designed for the treatment of recurrent respiratory papillomatosis (RRP), a rare and chronic condition linked to HPV, affecting the respiratory tract. At various points, company officials expressed optimism around an impending application for accelerated approval of INO-3107 from the U.S. Food and Drug Administration (FDA), indicating a transition towards full commercial viability.

Irregularities Alleged in the Class Action

Despite positive messaging regarding commercial prospects and regulatory trajectories, the class action lawsuit alleges that company executives disseminated materially false and misleading information concerning Inovio's business operations and prospects. Allegations suggest that crucial aspects of the manufacturing processes associated with the CELLECTRA device were deficient, negatively impacting the anticipated submission timeline of the INO-3107 Biologics License Application (BLA) to the FDA.

Defendants had previously projected that they would complete a rolling submission of the INO-3107 BLA by the latter half of 2024. However, the suit contends the company lacked sufficient justification for accelerated approval from the FDA, with claims that product eligibility was overstated, leading to misleading public statements made by executives.

The situation escalated when truth began to unfold publicly on August 8, 2024, during which Inovio disclosed a significant delay in the submission of the INO-3107 BLA, pushing it to mid-2025, a full year later than earlier forecasts. Following this announcement, Inovio's stock price dropped by over 3%, signaling investor discontent.

Subsequent revelations in December 2025 further diminished investor confidence when the FDA opted for a standard review of the INO-3107 BLA, denying the designation of accelerated approval and indicating inadequacies in the submitted data. Inovio's share price suffered a substantial decline, falling nearly 25% overnight in reaction to the news

Pomerantz LLP's Continued Advocacy

Pomerantz LLP, a prominent law firm recognized for its involvement in corporate and securities class action litigation, has established a notable history of fighting for the rights of investors wronged by corporate misconduct. Founded more than 85 years ago, the firm has seen resounding success in recovering billions for affected clients in previous cases. This case against Inovio Pharmaceuticals underscores their ongoing commitment to ensuring accountability and safeguarding investors' rights in the face of potential corporate wrongdoing.

For investors looking for more information or wishing to join the class action lawsuit, Pomerantz urges direct communication through their contact channels. Interested parties may reach out to Danielle Peyton by email or phone, as detailed in their public announcements.

Conclusion

As legal proceedings unfold, the implications of this class action lawsuit against Inovio Pharmaceuticals highlights critical issues around corporate transparency, ethical communication with investors, and the overarching regulatory framework guiding biotech firms. The outcomes of this case may not only shape future investor relations with Inovio but could also serve as a precedent for similar actions within the biotechnology industry.